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Abstract: Duchenne Muscular Dystrophy (DMD) is a common, inherited, incurable, fatal 
muscle wasting disease caused by deletions that disrupt the reading frame of the DMD 
gene such that no functional dystrophin protein is produced. Antisense oligonucleotide 
(AO)-directed exon skipping restores the reading frame of the DMD gene, and truncated, 
yet functional dystrophin protein is expressed. The aim of this study was to assess the 
efficiency of two novel rigid, cationic carotenoid lipids, C30-20 and C20-20, in the 
delivery of a phosphorodiamidate morpholino (PMO) AO, specifically designed for the 
targeted skipping of exon 45 of DMD mRNA in normal human skeletal muscle primary 
cells (hSkMCs). The cationic carotenoid lipid/PMO-AO lipoplexes yielded significant 
exon 45 skipping relative to a known commercial lipid, 1,2-dimyristoyl-sn-glycero-3-
ethylphosphocholine (EPC). 
Keywords: cationic lipid; carotenoid; antisense oligonucleotide; exon skipping; Duchenne 
muscular dystrophy 
 
OPEN ACCESS
Molecules 2012, 17                            
 
1139
1. Introduction 
In a physiological context, carotenoids are best known as antioxidants electron donors to noxious 
radicals [1] and quenchers of harmful singlet oxygen [2]. Carotenoids show further anticancer [3] and 
antistroke activity [4], besides other not yet fully exploited therapies [5], together with the precedent 
article we present here, to the best of our knowledge, the first application of carotenoids in gene 
transfection. 
Antisense oligonucleotides (AOs) are single-stranded DNA molecules, typically 13–25 nucleotides 
in length, synthesized to be complimentary to a unique RNA sequence. Antisense therapy is a form of 
treatment for genetic disorders for which a mutation of the genetic sequence of a particular gene is 
known to be responsible for a particular disease. In antisense therapy, the AO binds to the messenger 
RNA (mRNA) produced by that gene to inactivate it. Alternatively, the AO might be targeted to bind a 
splicing region on a pre-mRNA and modify the defective exon content of an mRNA so as to open the 
reading frame and allow the production of an essential protein product. 
Interest in AO therapy has recently focused on addressing vital medical needs, such as cancer, viral 
infections, muscular and neurological diseases. Duchenne Muscular Dystrophy (DMD) is an incurable 
muscle wasting disease caused by a vast number of deletions that disrupt the reading frame of the 
DMD gene, so that no functional dystrophin protein is produced. Antisense oligonucleotide (AO) 
directed exon skipping restores the reading frame of the DMD gene, and truncated, yet functional 
dystrophin protein is expressed. While recent reports have shown the potential for AOs to ameliorate 
DMD [6–11], numerous anatomic and cellular barriers remain that prevent this therapy from realizing 
its full potential. Much effort over recent years has been focused on improving the delivery of AOs 
using both viral and non-viral carriers. While viral delivery is generally regarded as more effective, 
this approach has a number of drawbacks, specifically large-scale production cost, limited cargo 
capacity, safety concerns and the potential for an immune response against the viral vector. Although 
non-viral agents such as lipids and polymers have much lower transfection efficiencies compared to 
their viral counterparts, they are cheaper and easier to produce in bulk, they are not limited in their 
cargo capacity and can be administered repeatedly. 
In the present study we report what is, to our knowledge, the first use of carotenoid-derived cationic 
lipids as delivery vectors of genetic material. Two novel cationic lipids, C30-20 and C20-20 (Figure 1), 
synthesized from carotenoic and retinoic acid (C30- and C20-acid), respectively, combined with a 
flexible icosan-1-ol chain coupled through a phosphocholine headgroup, were used to formulate 
lipoplexes with phosphorodiamidate morpholino (PMO) AOs designed to specifically target exon 45 
skipping of the DMD mRNA and delivered into normal human skeletal muscle primary cells 
(hSkMCs). Skipping of exon 45 would have the potential to treat 8.1% of DMD patients, the second 
highest percentage of patients after skipping of exon 51 (13%) [12]. 
2. Results and Discussion 
2.1. Synthesis of the Cationic Carotenoid Lipids C30-20 and C20-20 
The carotenoid lipids C30-20 and C20-20 were synthesized from commercial C30-carotenoid ester 
and C20-acid (retinoic acid). All intermediates and final products were purified after each step and 
Molecules 2012, 17                            
 
1140
fully characterized by thin-layer chromatography, ultraviolet-visible spectroscopy, low and high 
resolution mass spectrometry, 1H-, 13C- and 31P-NMR. All analytical data were found to be in 
accordance with known related compounds previously synthesized in our lab, and the detailed 
synthesis of C30-20 and C20-20 will be published elsewhere, together with the synthesis of other 
lipids of the C30-n and C20-n series. The structures of C30-20, C30-30, 1,2-dimyristoyl-sn-glycero-3-
ethylphosphocholine (EPC) and cholesterol are shown in Figure 1. 
Figure 1. Structures of cationic carotenoid lipids C30-20 and C20-20, together with 
commercially available cationic lipid EPC, and neutral co-lipid, cholesterol. 
 
2.2. Verification of Annealing PMO to Leash 
Verification that the leash had annealed to the PMO was confirmed by agarose gel electrophoresis. 
Aliquots of leash alone and leashed PMO were run on a 3% agarose gel. The PMO and leash had 
annealed successfully as an increase in size (i.e., slower moving band) was evident in leashed PMO 
relative to PMO alone (results not shown). 
2.3. Gel Retardation Assay 
PMO are uncharged molecules and will not migrate in agarose in a manner comparative to 
conventional deoxynucleic acids. The leash moiety does add charge and allows electrophoretic 
migration, thus enabling gel retardation evaluation. However, molecular weight comparisons with 
dsDNA migration markers cannot be made. Nevertheless, the size designation of 57 nt is denoted 
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beside the gel image in Figure 2, as this corresponds to the 30 mer PMO annealed with the 27 mer 
leash that contains 17 complimentary bases, leaving a 10 mer overhang. Complexation of negatively 
charged leashed PMO-AO with the cationic lipids results in a neutral particle once the negative 
charges of the nucleotides are paired with an equimolar amount of positively charged lipid molecules. 
Full gel retardation would then be expected once this equimolar pairing of (+/−) charges is achieved. 
However, structural and physicochemical differences between lipids may result in different packing 
properties of the various lipid/PMO-AO complexes. Complete gel retardation is not always observed 
with a 1:1 +/− charge ratio, suggesting that the properties of the various lipid/PMO AO lipoplexes are 
sensitive to the nature of the cationic lipid.  
Figure 2. Gel retardation assay of EPC/Chol/PMO AO, C20-20/Chol/PMO AO and  
C30-20/Chol/PMO AO at (+/−) molar charge ratios 0.1:1 up to 20:1; low molecular weight 
marker run through a 3% TBE-agarose gel impregnated with the DNA gel stain, ethidium 
bromide. The gel was visualized using a Geliance transilluminator. 
 
 
Lipid/PMO AO lipoplexes were prepared at various (+/−) molar charge ratios (nitrogen/phosphorus, 
or N/P ratios) ranging from 20:1–0.1:1 for lipoplexes EPC/Chol/PMO,  
C30-20/Chol/PMO and C20-20/Chol/PMO. The results of the gel retardation assay revealed that the 
C20-20/Chol/PMO complex resulted in the highest level of retention at a charge ratio of 20:1  
(Figure 2). Neither the EPC/Chol/PMO or C30-20/Chol/PMO lipoplexes revealed complete retention 
even at charge ratios as high as 20:1. 
2.4. Qualitative Assessment of Cell Viability 
At low (+/−) molar charge ratios (0.05:1 up to 0.25:1), the carotenoid lipid/PMO lipoplexes were 
well tolerated by hSkMCs upon visual inspection at 24 h, but some cell toxicity was evident at the 
higher (+/−) molar charge ratio of 0.5:1 for both carotenoid lipid/PMO lipoplexes tested (Figure 3). 
2.5. Reverse Transcriptase-PCR Results 
To verify the efficiency of the lipoplex formulations for delivery of the targeted AO, hSkMCs were 
transfected with PMO AO oligomers specifically targeted for skipping exon 45 of the mRNA, and 
RNA was extracted after 24 h. As the levels of skipped transcript are generally very small relative to 
the full-length transcript, nested reverse transcriptase-PCR (RT-PCR) on the harvested RNA was 
required. RT-PCR was performed on 200 ng RNA from hSkMCs treated with three different lipoplex 
formulas, namely EPC/Chol/PMO, C30-20/Chol/PMO and C20-20/Chol/PMO.  
 57 nt 
Molecules 2012, 17                            
 
1142
Figure 3. Qualitative cell viability assessment by light microscopy of hSkMCs transfected 
with lipoplex formulations C20-20/Chol/PMO AO (A–D) and C30-20/Chol/PMO AO  
(E–H) at (+/−) molar charge ratios of 0.05:1 (A, E), 0.1:1 (B, F) 0.25:1 (C, G) and 0.5:1 
(D, H) at 24 h. 
 
Agarose gel electrophoresis separation of products for charge ratios up to 0.5:1 for each lipid is 
shown in Figure 4 (results not shown for charge ratios 0.05:1).  
Figure 4. (A)–(C) Comparison of efficiency of various lipid/PMO AO complexes (each 
performed in triplicate) to induce skipping of exon 45 in RNA from hSkMCs. Nested  
RT-PCR was performed on 200 ng from hSkMCs treated with lipoplex formulations, 
EPC/Chol/PMO (A), C20-20/Chol/PMO (B) and C30-20/Chol/PMO (C) at 250 nmol/L at 
the ratios indicated. The obtained products were separated by agarose gel (1.5%) 
electrophoresis against Hyper ladder IV. The full-length product (exons 44-48) is 657 bp 
and the skipped product (exons 44, 46-48) is 481 bp in size. Non-transfected controls are 
shown in D. 
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Figure 4. Cont. 
 
Future work will therefore include time-course studies to establish in further detail the efficacy of 
our novel vectors. To normalize for RNA quality within the RT-PCR assay, amplification of the 
housekeeping gene, ribosomal 18s was also performed (Figure 5, results not shown for charge ratios 
0.05:1).  
Figure 5. RT-PCR amplification of ribosomal 18s housekeeping gene to assess 
comparative RNA quality between samples transfected with various lipid/PMO AO 
complexes. 100 ng of RNA harvested from hSkMCs treated with lipoplex formulations, 
EPC/Chol/PMO, C20-20/Chol/PMO and C30-20/Chol/PMO at 250 nmol/L at the ratios 
indicated was subjected to RT-PCR amplification. The obtained products were separated 
by agarose gel (2.5%) electrophoresis against Hyper ladder V. The expected product is 
around 130 bp in size. 
 
 
 
Equal amounts of RNA (100 ng) were subjected to RT-PCR amplification; the poor quality of RNA 
harvested from cells transfected with C20-20/Chol/PMO at a charge ratio of 0.5:1 is evident. This 
explains the failure of exon 44-48 amplification by nested RT-PCR in these samples. The poor RNA 
quality is likely to be the result of the toxicity seen for C20-20/Chol/PMO at the charge ratio of 0.5:1 
(Figure 3, D). Semi-quantification of levels of skipping was assessed using densitometry and is shown 
in Figure 6. A significantly higher level of skipping was observed for the two carotenoid lipids over a 
range of charge ratios compared to the same charge ratios of EPC lipid. The greatest level of exon 45 
skipping for lipid C30-20 was observed at 68.3 ± 25.9% at a (+/−) charge ratio of 0.5:1 (p = 0.0493, 
paired t-test relative to the same charge ratio of EPC), and for lipid C20-20 was 29.7 ± 2.3%, at a (+/−) 
charge ratio of 0.25:1 (p = 0.0301, paired t-test, relative to the same charge ratio of EPC) with 250 nM 
leashed PMO (Figure 6). Charge ratios beyond 1:1 for both carotenoid formulations resulted in 
significant cell death (data not shown). At the (+/−) charge ratios tested, the two carotenoid lipids 
achieved greater exon 45 skipping in hSkMCs relative to the commercial lipid, EPC. A limitation of 
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this study was the short differentiation time interval of twenty-four h used. As a result, the cells may 
not have been fully differentiated. This time point was chosen on the basis of previous experience from 
our lab with the commercial reagent, lipofectin (Invitrogen) [9,14]. Under identical experimental 
conditions in parallel experiments, up to 50% exon skipping was observed when using the commercial 
reagent, lipofectin (Invitrogen) at a ratio of 1:4 (data not shown).  
Figure 6. Comparison of lipoplex formulations (EPC/Chol/PMO, C30-20/Chol/PMO and 
C20-20/Chol/PMO at 250 nmol/L) to produce exon 45 skipping in hSkMCs over a range of 
charge ratios. 
 
3. Experimental 
3.1. Materials and Methods 
Lipids EPC and cholesterol were obtained from Youjin Corporation (Seoul, Korea) and Avanti 
Polar Lipids (Alabaster, USA), respectively. PMO AO h45A30/1 (sequence available on request) was 
purchased from Gene Tools (Philomath, OR, USA), complementary leash h45A30/1L (sequence 
available on request) and RT-PCR primers from Eurofins MWG Operon (Ebersberg, Germany). 
Normal human skeletal muscle primary cells (hSkMCs) were purchased from TCS cellworks 
(Buckingham, UK), skeletal muscle cell growth and differentiation media plus supplements from 
PromoCell GmbH (Heidelberg, Germany), GeneScript RT-PCR system kit and 2× PCR Master Mix 
with cresol red from GeneSys Ltd. (Camberley, Surrey, UK). QIAshredder kit and RNeasy Mini kit 
were purchased from Qiagen Ltd. (Crawley, UK). Agarose, buffers and antibiotics were purchased 
from Invitrogen Ltd. (Paisley, UK). All solvents and chemical reagents were obtained from Sigma 
Aldrich (St. Louis, MO, USA) unless otherwise stated. Dichloromethane was obtained from Alfa 
Aesar (West Hill, MA, USA). 
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3.2. Synthesis of Cationic Carotenoid Lipids, C30-20 and C20-20 
Lipids C30-20 and C20-20 were synthesized from commercial C30-carotenoid ester and C20-acid 
(retinoic acid). 2-Chloro-1,3,2-dioxaphospholane was reacted with dimethylamine, ethylene glycol, 
Br2 and 1-icosanol to bromoethylicosylhydroxyethyl phosphate, which was esterified with  
β-apo-8´carotenoic acid (C30 acid) and retinoic acid (C20 acid), followed by aminolysis to the lipids 
C30-20 and C20-20, respectively. The details will be published elsewhere. 
3.3. Liposome and Lipoplex Formulation 
3.3.1. Ethanolic stock Solutions 
Ethanolic stock solutions were made for each individual cationic lipid and co-lipid by dissolving a 
known amount of lipid in dichloromethane in a round-bottom flask. The dichloromethane solutions 
were placed on a rotary evaporator for two hours to obtain a film. The film was dissolved in a known 
amount of anhydrous alcohol, and once dissolved the alcohol stock was stored at −80 °C. 
3.3.2. Liposome Formulations 
Hydrated liposomal (cationic lipid/co-lipid) formulations (namely, EPC/Chol, C30-20/Chol and 
C20-20/Chol, all at a cationic lipid/co-lipid molar ratio of 3:2) were generated from stock solutions 
from thin films by combining the required amounts of each alcohol solution of lipid and co-lipid, as 
determined by calculation of desired ratios, and removing the ethanol under reduced pressure. The thin 
films were then dissolved in a known amount of sterile water, followed by sonication to give a 2 mM 
final solution of hydrated stocks. These hydrated stock liposomal solutions were stored overnight at  
4 °C. Before use, the hydrated stocks were warmed to 37 °C for 5 min in a water bath, then sonicated 
for 30 min. 
3.3.3. Preparation of Leashed PMO-AO 
PMOs are unable to enter cells in vitro due to their lack of charge. Charge is introduced by 
annealing the PMOs to complementary phosphorothioate-capped oligodeoxynucleotide leashes. The 
complementary sequence of the PMO is 17 bases long, with tails at either end. The tails of the leash 
are always of the sequence ‘gattg’ (5’ to 3’) at the 5’ end of the PMO, and ‘gtgat’ (5’ to 3’) at the 3’ 
end of the PMO. Leash/PMO stocks were prepared at 100 µM by mixing 12.5 µL 10× PBS with  
7.5 µL RNase-, DNase-free H2O, 25 µL leash (200 µM) and 5 µL PMO (1 mM) and annealed by 
gradual decrease in temperature from 94 °C in a thermal cycler, according to the method 
recommended by Gebski et al. [13]. Leashed PMOs were stored at 4 °C for a maximum of 6 weeks. 
3.3.4. Verification of Annealing PMO to Leash 
Verification of annealing PMO to leash was established by running aliquots of leash alone and 
leashed PMO on a 3% agarose gel; an increase in size should be evident in leashed PMO relative to 
PMO alone, if PMO and leash have hybridized effectively. 
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3.3.5. Lipid/PMO-AO Lipoplexes 
Lipid/PMO-AO lipoplexes were formulated by adding equal volumes of liposome solution to  
PMO-AO at the desired charge ratio. The liposome particles were serially diluted to obtain varying 
cationic lipid/leash (N/P, or +/−) molar charge ratios at a given volume. 
3.4. Bioassays 
3.4.1. Gel Retardation Assay  
A gel retardation assay is a common technique, used in the context of this proposal to study the 
interaction between cationic lipids and AO. Briefly, the lipid/PMO-AO complexes, incubated in  
20 mM HEPES, pH 5.5 were mixed with loading dye (bromophenol blue) and loaded onto the 3% 
agarose gel impregnated with ethidium bromide. The gel was then run at 105 V for 120 min in TBE 
buffer. The rate at which different molecules move through the gel was determined by their size and 
charge, and to a lesser extent, their shape. 
3.4.2. Transfection of normal human skeletal muscle primary cells (hSkMCs) 
Cells were seeded in a 6-well culture plate at a density of 8 × 104 cells/well and cultured till ~80% 
confluence. The growth medium was removed and replaced with 2 mL pre-warmed differentiation 
medium and cells incubated at 37 °C, 5% CO2 for 1 h. During this 1-hour incubation with 
differentiation medium, the lipid:leashed PMO:DMEM mixes were prepared and incubated for 30 min 
at RT. The differentiation medium was removed and wells were rinsed with 2 mL DMEM. A 1 mL 
aliquot of lipid:PMO:DMEM mix was added into each well and cells were incubated at 37 °C, 5% 
CO2 for 4 h. The lipid:PMO:DMEM mix was then replaced with 2 mL pre-warmed differentiation 
media. RNA was extracted after 24 h. 
3.4.3. RNA Extraction and Purification 
RNA extraction and purification was performed using the QIAgen RNeasy mini kit and has 
previously been described [14]. In brief, cells were lysed with buffer RLT, and lysates were 
homogenized with a QIAshredder column. RNA was purified with a RNeasy mini column containing 
an silica-gel membrane, washed with RW1 and RPE buffers and eluted with RNase-free H2O and the 
concentration were measured using a ND-1000 Spectrophotometer (©Nano Drop).  
3.4.4. RT-PCR 
For assessment of exon 45 skipping 200 ng RNA was amplified by semi-nested RT-PCR. Primers 
used in the first round were forward h43f (5’-ACAACAAAGCTCAGGTCGGA-3’) and reverse h49r 
(5’ ATCTCTTCCACATCCGGTTG. RT-PCR was performed at 45 °C for 30 min, 92 °C for 5 min; 
then 20 cycles of 92 °C for 30 s, 60 °C for 30 s, 68 °C for 90 s; followed by 68 °C for 10 min in a 
reaction mix containing 300 nM of each primer, 200 μM dNTPs, 1.5 mM MgSO4 and 0.625 U 
GeneScript enzyme mix. A 2 μL aliquot of the first round product was further amplified in a second 
round using forward h44f (5’-CAGTGGCTAACAGAAGCTGAAC-3’) and reverse h48r  
Molecules 2012, 17                            
 
1147
(5’-CTTATGGGAGCACTTACAAGC-3’) primers. PCR was performed at 92 °C for 2 min, then 30 
cycles of 92 °C for 30 s, 66 °C for 30 s and 68 °C for 90 s; followed by 68 °C for 10 min in a reaction 
mix containing 300 nM of each primer, 0.625 U Taq polymerase, 200 μM dNTPs and 1.5 nM MgCl2. 
For assessment of RNA quality between samples transfected with various lipid/PMO AO complexes, 
100 ng of RNA was subjected to RT-PCR amplification using ribosomal 18s housekeeping primers. 
PCR amplification was performed at 92 °C for 2 min, then 30 cycles of 92 °C for 30 s, 60 °C for 30 s 
and 68 °C for 90 s, followed by 68 °C for 10 min in a reaction mix containing 100 nM of each primer, 
0.625 U Taq Polymerase, 200 μM dNTPs and 1.5 nM MgCl2. The obtained products were separated 
by agarose gel (2.5%) electrophoresis against Hyper ladder V. 
4. Conclusions 
The novel cationic carotenoid lipids C30-20 and C20-20 were formulated into liposomes with the 
neutral co-lipid, cholesterol, as was the commercial cationic lipid, EPC. Each of these was 
subsequently formulated into lipoplexes containing leashed PMO capable of producing exon 45 
skipping in hSkMCs; 29.7% exon skipping was achieved with C20-20/Cholesterol at a N/P (+/−) 
molar ratio of 0.25:1, and 68.3% with C30-20/Cholesterol, each at a N/P (+/−) molar charge ratio of 
0.5:1. The C30 carotenoids performed significantly better at lower charge ratios as compared to the 
commercial cationic lipid, EPC. This study shows that carotenoid lipids have potential as delivery 
vectors for antisense oligonucleotides for exon skipping in Duchenne Muscular Dystrophy. 
Acknowledgments 
This publication was made possible by grants from the Qatar National Research Fund under the 
Undergraduate Research Experience Program, award UREP09-104-3-020, and the National Priorities 
Research Program, award NPRP08-705-3-144. Its contents are solely the responsibility of the authors 
and do not necessarily represent the official views of the Qatar National Research Fund. We thank  
H. Ernst, BASF SE, Ludwigshafen Germany for a generous gift of C30-acid. 
Conflict of Interest 
The authors declare no conflict of interest. 
References and Notes 
1. Krinsky, N.I. Carotenoids as antioxidants. Nutrition 2001, 17, 815–817. 
2. Baltschun, D.; Beutner, S.; Briviba, K.; Martin, H.-D.; Paust, J.; Peters, M.; Röver, S.; Sies, H.; 
Stahl, W.; Steigel, A.; et al. Singlet Oxygen Quenching Abilities of Carotenoids. Liebigs Ann. 
1997, 1997, 1887–1893. 
3. Sharoni, Y.; Danilenko, M.; Dubi, N.; Ben-Dor, A.; Levy, J. Carotenoids and transcription. Arch. 
Biochem. Biophys. 2004, 430, 89–96. 
4. Lockwood, S.F.; Gross, G.J. Disodium disuccinate astaxanthin (Cardax): Antioxidant and 
antiinflammatory cardioprotection. Cardiovasc. Drug Rev. 2005, 23, 199–216. 
Molecules 2012, 17                            
 
1148
5. Krinsky, N.I.; Johnson, E.J. Carotenoid actions and their relation to health and disease. Mol. 
Aspects Med. 2005, 26, 459–516. 
6. Goemans, N.M.; Tulinius, M.; van den Akker, J.T.; Burm, B.E.; Ekhart, P.F.; Heuvelmans, N.; 
Holling, T.; Janson, A.A.; Platenburg, G.J.; Sipkens, J.A.; et al. Systemic administration of 
PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 2011, 364, 1513–1522. 
7. Popplewell, L.J.; Adkin, C.; Arechavala-Gomeza, V.; Aartsma-Rus, A.; de Winter, C.L.; Wilton, 
S.D.; Morgan, J.E.; Muntoni, F.; Graham, I.R.; Dickson, G. Comparative analysis of antisense 
oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future 
clinical trials. Neuromuscul. Disord. 2010, 20, 102–110. 
8. Kinali, M.; Arechavala-Gomeza, V.; Feng, L.; Cirak, S.; Hunt, D.; Adkin, C.; Guglieri, M.; 
Ashton, E.; Abbs, S.; Nihoyannopoulos, P.; et al. Local restoration of dystrophin expression with 
the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: A single-blind,  
placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009, 8, 918–928. 
9. Popplewell, L.J.; Trollet, C.; Dickson, G.; Graham, I.R. Design of phosphorodiamidate 
morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol. 
Ther. 2009, 17, 554–561. 
10. Arechavala-Gomeza, V.; Graham, I.R.; Popplewell, L.J.; Adams, A.M.; Aartsma-Rus, A.; Kinali, 
M.; Morgan, J.E.; van Deutekom, J.C.; Wilton, S.D.; Dickson, G.; et al. Comparative analysis of 
antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin  
pre-mRNA splicing in human muscle. Hum. Gene Ther. 2007, 18, 798–810. 
11. van Deutekom, J.C.; Janson, A.A.; Ginjaar, I.B.; Frankhuizen, W.S.; Aartsma-Rus, A.;  
Bremmer-Bout, M.; den Dunnen, J.T.; Koop, K.; van der Kooi, A.J.; Goemans, N.M.; et al. Local 
dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 2007, 357,  
2677–2686. 
12. Aartsma-Rus, A.; Fokkema, I.; Verschuuren, J.; Ginjaar, I;, van Deutekom, J.; van Ommen, G.J.; 
den Dunnen, J.T. Theoretic applicability of antisense-mediated exon skipping for Duchenne 
muscular dystrophy mutations. Hum. Mutat. 2009, 30, 293–299. 
13. Gebski, B.L.; Mann, C.J.; Fletcher, S.; Wilton, S.D. Morpholino antisense oligonucleotide 
induced dystrophin exon 23 skipping in mdx mouse muscle. Hum. Mol. Genet. 2003, 12,  
1801–1811. 
14. Popplewell, L.J.; Graham, I.R.; Malerba, A.; Dickson, G. Bioinformatic and functional 
optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic 
modulation of RNA splicing in muscle. Methods Mol. Biol. 2011, 709, 153–178. 
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
